A Randomized, Open-Label, Single-Dose Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
Latest Information Update: 11 Oct 2024
At a glance
- Drugs HCP1904-1 (Primary)
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
- 08 Oct 2024 Status changed from not yet recruiting to completed.
- 14 Jun 2022 New trial record